Speakers

Expand/Collapse

Adam Byrne
Professor
Imperial College London

Day 2

Wednesday March 9, 2022

2:30 pm | The Role of Macrophage Metabolic Reprogramming During Pulmonary Fibrosis

Annie Gilbert
Clinical Development & Operations Patient & Site Engagement Lead
Boehringer Ingelheim

Day 2

Wednesday March 9, 2022

10:00 am | Panel Discussion: Bringing the Patient Voice into Clinical Trial Design and Conduct

Carsten Ehrhardt
Professor of Pharmacy
Trinity College Dublin

Pre-Conference Day

Monday, March 7, 2022

12:00 pm | Integrating Inhaled Therapeutics with ILD Mechanisms to Streamline Your Drug Delivery

11:30 am | Considerations for Inhaled Drug Delivery

Track A, AM

Monday, March 7

2:00 pm | Moderated Discussion: Analyzing Biologics, Small Molecules & Antibodies for the Treatment of ILD to Determine Which One is Most Easily Inhaled, Nebulized & Absorbed by the Alveoli

Track A, PM

Monday, March 7

3:30 pm | Advantages & Disadvantages of Different Molecule Types for Inhaled Drug Delivery

Cheryl Nutter
Senior Vice President Research & Development
Three Lakes Foundation

Day 2

Wednesday March 9, 2022

4:30 pm | How Three Lakes Foundation is Catalyzing Efforts to Benefit Patients With ILD and Pulmonary Fibrosis

Pre-Conference Day

Monday, March 7, 2022

10:55 am | Opening Remarks

Track A, AM

Monday, March 7

1:00 pm | Investigating Inhaled Drug Delivery for Interstitial Lung Disease Afternoon
Chair:

Craig Conoscenti
Medical Expert ILD Respiratory Clinical Development & Medical Affairs
Boehringer Ingelheim

Day 2

Wednesday March 9, 2022

9:00 am | Strategically Leveraging ILD Clinical Trials to Further Our Understanding of The Progressive Pulmonary Fibrosis Phenotype & Identify Novel Outcomes in Clinical Trials

David Barber
Professor of Machine Learning
UCL

Day 1

Tuesday March 8, 2022

11:00 am | OSIC Project – Exploring Imaging Based Biomarkers, CT Scans/ Data Collection to Predict FVC Decline

David Lynch
Professor of Radiology
National Jewish Health

Track B, AM

Monday, March 7

12:55 pm | Exploring Biomarkers for ILD Clinical Trials Afternoon
Chair:

Dinesh Khanna
Professor
University of Michigan

Day 1

Tuesday March 8, 2022

9:30 am | Designing Trials for Inflammatory ILDs in 2022 & Beyond: Spotlight on Ssc-ILD

Elizabeth Renzoni
Consultant Respiratory Physician, Honorary Senior Lecturer
Imperial College London

Day 1

Tuesday March 8, 2022

2:15 pm | Exploring Endpoints in the Context of Inflammatory ILDs: Debating Which Factors You Must Measure to Accurately Assess the Efficacy of Treatment in Inflammatory vs Fibrotic ILDs

Eric White
Senior Clinical Program Lead
Boehringer Ingelheim

Day 2

Wednesday March 9, 2022

9:30 am | Looking Beyond IPF: Utilizing Lessons Learned from IPF Clinical Trials to Inform & Optimize Your ILD Trial Design & Execution

Fabio Stellari
Molecular Imaging Facility-Experimental Pharmacology & Translational Science Senior Scientist
Chiesi Pharmaceuticals

Day 1

Tuesday March 8, 2022

3:30 pm | Investigating Imaging Technologies in Lung Fibrosis Drug Discovery

Farrell Simon
Vice President & Head of US Marketing
Trevi Therapeutics

Day 1

Tuesday March 8, 2022

1:00 pm | Exploring the Impact & Importance of Quality of Life on the Patient Journey

Glenn Rosen
Chief Scientific Officer
Optikira & Biomotiv

Day 2

Wednesday March 9, 2022

4:00 pm | Revealing What Steps You Must Take to Successfully Identify & Validate Novel ILD Therapeutic Targets which Target Lung Epithelial injury

Jason Laufer
Chief Executive Officer
Remedy Cell

Track A, PM

Monday, March 7

3:30 pm | Advantages & Disadvantages of Different Molecule Types for Inhaled Drug Delivery

Jessica Shore
Vice President -Research and Programs
Pulmonary Fibrosis Foundation

Day 2

Wednesday March 9, 2022

8:55 am | Chair’s Opening Remarks

Margaret Neighbors
Principle Scientist
Genentech

Track B, AM

Monday, March 7

2:30 pm | Considerations for Clinical Trial Biomarker Selection

2:00 pm | Learning how to Use Biomarkers to Distinguish Patients with Fibrotic vs Inflammatory ILD in Order to Strategically Stratify Trial Populations & Maximize Trial Efficiency

Matt Bradley
CEO, Chairman & Founder
SAJE Pharma

Day 2

Wednesday March 9, 2022

12:00 pm | Single vs Multiple Benefit Drugs for ILD

Meera Ramanujam
Executive Director, Immunology and Translational Research
Aro Biotherapeutics

Day 1

Tuesday March 8, 2022

8:25 am | Chair’s Opening Remarks

Michael Timaner
Vice President, Research & Development
Remedy Cell Ltd

Track A, AM

Monday, March 7

2:30 pm | Harnessing the Therapeutic Power of Secretomes to Treat IPF & the Challenges of Optimizing Inhaled Drug Delivery

Nicolas Guisot
Research Fellow & Project Leader
Redx Pharma

Day 2

Wednesday March 9, 2022

3:30 pm | Selective Inhibition of ROCK2: Promising Approach to Target Fibrosis

Nina Patel
Director – Clinical Development & Medical Affairs ILD
Boehringer Ingelheim

Day 1

Tuesday March 8, 2022

9:00 am | Minding the Gap: SES in ILD Care & Trials

Paolo Cameli
Pulmonologist
University of Siena

Day 1

Tuesday March 8, 2022

11:30 am | Exploring Biomarkers for Differential Diagnosis of Interstitial Lung Diseases

Peter Fernandes
Vice President & Chief Regulatory, Quality & Safety Officer
Bellerophon Therapeutics

Day 1

Tuesday March 8, 2022

1:45 pm | Devising & Developing Composite Endpoints Which are Realistic & Achievable to Use in Your Next Clinical Trial

Pre-Conference Day

Monday, March 7, 2022

12:00 pm | Integrating Inhaled Therapeutics with ILD Mechanisms to Streamline Your Drug Delivery

11:00 am | Deep Diving into Delivery Mechanisms: Comparing & Contrasting Inhaled vs Systemic Drug Delivery in the Context of ILD Treatment

Rohit Batta
Chief Medical Officer
Vicore Pharma

Day 2

Wednesday March 9, 2022

11:30 am | Developing Therapies for Rare Lung Diseases: ILD 101

Sabine Pinnetti
Clinical Development & Operations Lead
Boehringer Ingelheim

Day 2

Wednesday March 9, 2022

10:00 am | Panel Discussion: Bringing the Patient Voice into Clinical Trial Design and Conduct

Shane Olwill
Senior Vice President & Chief Development Officer
Pieris Pharmaceuticals

Track A, AM

Monday, March 7

2:00 pm | Moderated Discussion: Analyzing Biologics, Small Molecules & Antibodies for the Treatment of ILD to Determine Which One is Most Easily Inhaled, Nebulized & Absorbed by the Alveoli

Track A, PM

Monday, March 7

3:30 pm | Advantages & Disadvantages of Different Molecule Types for Inhaled Drug Delivery

Shannon Turley
Vice President of Cancer Immunology Discovery
Genentech

Day 2

Wednesday March 9, 2022

2:00 pm | Evolution of Multicellular Hubs in the Tumor Microenvironment & their Relevance for ILD Drug Development

Sharon Lee
Executive Director
Canadian Pulmonary Fibrosis Foundation

Day 2

Wednesday March 9, 2022

10:00 am | Panel Discussion: Bringing the Patient Voice into Clinical Trial Design and Conduct

Shervin Assassi
Director of the Division of Rheumatology
The University of Texas

Track B, PM

Monday, March 7

3:30 pm | Enrichment Strategies on SSc-ILD Clinical Trials

Simon Walsh
Consultant Thoracic Radiologist, Machine Learning Scientist & Imaging Chair
Imperial College London

Day 1

Tuesday March 8, 2022

3:00 pm | Machine Learning & Interstitial Lung Disease: A Deep Dive

Stephen Christensen
Translational Systems Biologist-Immunologist
Pfizer

Day 1

Tuesday March 8, 2022

8:30 am | Comparing & Contrasting Fibrotic & Inflammatory ILDs in Order to Comprehensively Understand Key Differences in Their Development & Progression & Learning How This Influences Drug Development

Steve Jones
President
EUIPFF

Day 2

Wednesday March 9, 2022

10:00 am | Panel Discussion: Bringing the Patient Voice into Clinical Trial Design and Conduct

Susan Wood
Chief Executive Officer
Vida Lung

Day 1

Tuesday March 8, 2022

1:30 pm | Driving Efficiencies in ILD drug Trials Through Lung Intelligence: How Precision Imaging Biomarkers & an AI-Driven Cloud Platform are Helping Accelerate New Therapies to Patients

Tejaswini Kulkarni
Director of Interstitial Lung Disease Program
University of Alabama

Track B, AM

Monday, March 7

2:30 pm | Considerations for Clinical Trial Biomarker Selection

1:30 pm | Utilizing Biomarkers to Identify Patient Populations Which are More Receptive to Your ILD Therapeutic in Order to Design and Conduct Faster Trials in a Shorter Time Frame

Toby Maher
Director, Interstitial Lung Disease Program
USC

Track A, PM

Monday, March 7

4:00 pm | Practical Experience of Delivering Inhaled Drugs in Fibrotic Lung Disease

Vanessa Neins
Senior Scientist - Biology Lead Respiratory
Pieris Pharmaceuticals

Day 2

Wednesday March 9, 2022

1:30 pm | Update on Inhaled Drug Delivery: The Application of Anticalins in the Treatment of Lung Fibrosis